Bedrijfsoverzicht
Quantum-Si incorporated is a life sciences entity dedicated to developing a proprietary, universal, and single-molecule detection platform specifically applied to proteomics to facilitate next-generation protein sequencing. Operating within the healthcare sector and the medical devices industry, the company focuses on engineering high-resolution instruments capable of single-molecule, amino acid level resolution for its core products. The organization employs a workforce of 145 individuals and holds a total market capitalization of $160.22M, reflecting its valuation as a small-cap entity within the specialized biotechnology landscape. With annual revenue reaching $2.44M, the company's financial scale indicates a position as a niche player where revenue generation is currently constrained, likely due to the high capital expenditure required for research and development before achieving widespread commercial adoption. The significant disparity between the market cap and the relatively modest revenue stream suggests that the market is pricing in future potential from the Platinum and Platinum Pro NGPS instruments rather than current operational cash flow.
Financiële gezondheid
The company reported revenue of $2.44M for the trailing twelve months, yet recorded a net income of $-101,339,000 and an EBITDA of $-92,594,000, highlighting a severe structural deficit where operating expenses vastly outweigh total sales. This massive gap between revenue and net income reveals a cost structure characterized by exceptionally high burn rates, likely driven by extensive R&D investments, specialized manufacturing costs, or significant one-time expenses associated with bringing next-gen protein sequencing technology to market. The free cash flow stands at $-45,797,000, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating liquidity from its core business. Despite this cash burn, the company maintains a substantial cash balance of $162.91M, which provides a finite runway to sustain operations without immediate external financing, though the negative free cash flow limits financial flexibility for strategic acquisitions or rapid scaling. The gross margin is 47.3%, suggesting that the cost of goods sold for the medical devices is well-controlled relative to sales, while the operating margin of -4677.2% and profit margin of 0.0% reflect the intense pressure from overhead costs and the lack of profitability at the current scale. Regarding leverage, total debt is $4.17M against a cash hoard of $162.91M, resulting in a debt-to-equity ratio of 1.89 which, while appearing high numerically, represents a net cash position when liabilities are netted against cash holdings. The current ratio of 7.64 indicates robust short-term liquidity, as the company holds significantly more current assets than current liabilities, providing a strong buffer against short-term obligations. Finally, the return on equity is -46.5% and the return on assets is -24.6%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic in early-stage life sciences firms where earnings are negative while assets are being accumulated.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is -2.00, a negative figure that implies the market is attempting to value the stock based on anticipated future earnings recovery rather than historical performance. The price-to-book ratio stands at 0.73, indicating that the market values the company at a discount to its book value, which often occurs in capital-intensive industries where future growth potential is not yet reflected in current asset valuations. Alternative valuation metrics such as the price-to-sales ratio of 65.77 and the EV/EBITDA of -0.02 suggest that the stock is priced heavily on future revenue expectations, as traditional earnings-based multiples are currently inapplicable or negative. The stock has traded between a 52-week low of $0.69 and a 52-week high of $3.10, and without a specific current price provided in the facts, the valuation range indicates a high degree of speculative volatility where the price can fluctuate significantly from the low end of the trading band. The beta value of 3.09 signifies that the stock's price volatility is more than three times that of the broader market, meaning that price swings will be amplified relative to general market movements, reflecting the high risk associated with developing unproven single-molecule detection platforms.
Growth & Income
Revenue growth year-over-year is -62.2%, while earnings growth is N/A due to the absence of positive earnings in the previous period, indicating that the company is currently shrinking in terms of top-line sales rather than expanding its market share. Since earnings are negative, they cannot grow faster than revenue in a traditional sense, and the decline in revenue suggests that the company is facing challenges in commercializing its Platinum and Platinum Pro NGPS instruments or is in a phase of deliberate revenue contraction during product development cycles. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, which means the company retains all cash flow to reinvest into research, development, and the scaling of its proprietary detection platform rather than returning capital to shareholders. The overall growth and income profile is characterized by negative revenue momentum and a complete lack of current income distribution, typical for a life sciences company in the deep development stage where capital preservation is prioritized over immediate financial returns.